Literature DB >> 15475455

Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.

Kamel Izeradjene1, Leslie Douglas, Addison Delaney, Janet A Houghton.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis via the death receptors DR4 and DR5 in transformed cells in vitro and exhibits potent antitumor activity in vivo with minor side effects. Protein kinase casein kinase II (CK2) is increased in response to diverse growth stimuli and is aberrantly elevated in a variety of human cancers. Rhabdomyosarcoma tumors are the most common soft-tissue sarcoma in childhood. In this investigation, we demonstrate that CK2 is a key survival factor that protects tumor cells from TRAIL-induced apoptosis. We have demonstrated that inhibition of CK2 phosphorylation events by 5,6-dichlorobenzimidazole (DRB) resulted in dramatic sensitization of tumor cells to TRAIL-induced apoptosis. CK2 inhibition also induced rapid cleavage of caspase-8, -9, and -3, as well as the caspase substrate poly(ADP-ribose) polymerase after TRAIL treatment. Overexpression of Bcl-2 protected cells from TRAIL-induced apoptosis in the presence of the CK2 inhibitor. Death signaling by TRAIL in these cells was Fas-associated death domain and caspase dependent because dominant negative Fas-associated death domain or the cowpox interleukin 1beta-converting enzyme inhibitor protein cytokine response modifier A prevented apoptosis in the presence of DRB. Analysis of death-inducing signaling complex (DISC) formation demonstrated that inhibition of CK2 by DRB increased the level of recruitment of procaspase-8 to the DISC and enhanced caspase-8-mediated cleavage of Bid, thereby increasing the release of the proapoptotic factors cytochrome c, HtrA2/Omi, Smac/DIABLO, and apoptosis inducing factor (AIF) from the mitochondria, with subsequent degradation of X-linked inhibitor of apoptosis protein (XIAP). To further interfere with CK2 function, JR1 and Rh30 cells were transfected with either short hairpin RNA targeted to CK2alpha or kinase-inactive CK2alpha (K68M) or CK2alpha' (K69M). Data show that the CK2 kinase activity was abrogated and that TRAIL sensitivity in both cell lines was increased. Silencing of CK2alpha expression with short hairpin RNA was also associated with degradation of XIAP. These findings suggest that CK2 regulates TRAIL signaling in rhabdomyosarcoma by modulating TRAIL-induced DISC formation and XIAP expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15475455     DOI: 10.1158/1078-0432.CCR-04-0576

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  22 in total

1.  Bone marrow derived mesenchymal stem/stromal cells transduced with full length human TRAIL repress the growth of rhabdomyosarcoma cells in vitro.

Authors:  Helga Barti-Juhasz; Rudolf Mihalik; Katalin Nagy; Giulia Grisendi; Massimo Dominici; Istvan Petak
Journal:  Haematologica       Date:  2011-03       Impact factor: 9.941

Review 2.  Protein kinase CK2 in breast cancer: the CK2β regulatory subunit takes center stage in epithelial plasticity.

Authors:  Odile Filhol; Sofia Giacosa; Yann Wallez; Claude Cochet
Journal:  Cell Mol Life Sci       Date:  2015-05-20       Impact factor: 9.261

3.  Interaction of CSR1 with XIAP reverses inhibition of caspases and accelerates cell death.

Authors:  Zhong-Liang Zheng; Lang-Zhu Tan; Yan P Yu; George Michalopoulos; Jian-Hua Luo
Journal:  Am J Pathol       Date:  2012-06-08       Impact factor: 4.307

4.  Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8.

Authors:  Soonah Shin; Yoonmi Lee; Wooseok Kim; Hyeonseok Ko; Hyeyeon Choi; Kunhong Kim
Journal:  EMBO J       Date:  2005-09-29       Impact factor: 11.598

5.  Phosphorylation of serine 205 by the protein kinase CK2 persists on Pax3-FOXO1, but not Pax3, throughout early myogenic differentiation.

Authors:  Kevin N Dietz; Patrick J Miller; Andrew D Hollenbach
Journal:  Biochemistry       Date:  2009-12-15       Impact factor: 3.162

Review 6.  Protein kinase CK2 in health and disease: CK2: a key player in cancer biology.

Authors:  J H Trembley; G Wang; G Unger; J Slaton; K Ahmed
Journal:  Cell Mol Life Sci       Date:  2009-06       Impact factor: 9.261

7.  Analysis of cell type-specific expression of CK1 epsilon in various tissues of young adult BALB/c Mice and in mammary tumors of SV40 T-Ag-transgenic mice.

Authors:  Anja C Utz; Heidrun Hirner; Annette Blatz; Andreas Hillenbrand; Bernhard Schmidt; Wolfgang Deppert; Doris Henne-Bruns; Dietmar Fischer; Dietmar R Thal; Frank Leithäuser; Uwe Knippschild
Journal:  J Histochem Cytochem       Date:  2009-09-15       Impact factor: 2.479

8.  Inhibition of casein kinase 2 enhances the death ligand- and natural kiler cell-induced hepatocellular carcinoma cell death.

Authors:  H-R Kim; K Kim; K-H Lee; S J Kim; J Kim
Journal:  Clin Exp Immunol       Date:  2008-03-10       Impact factor: 4.330

Review 9.  Targeting CK2-driven non-oncogene addiction in B-cell tumors.

Authors:  E Mandato; S Manni; F Zaffino; G Semenzato; F Piazza
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

10.  IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1.

Authors:  M D Faye; S T Beug; T E Graber; N Earl; X Xiang; B Wild; S Langlois; J Michaud; K N Cowan; R G Korneluk; M Holcik
Journal:  Oncogene       Date:  2014-04-07       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.